Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Bristol-Myers Squibb Co News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,584.70 | 111.90 | -1.29% |
| CAC 40 | 7,726.20 | 60.58 | 0.79% |
| DAX 40 | 22,653.86 | 273.67 | 1.22% |
| Dow JONES (US) | 46,208.47 | 631.00 | 1.38% |
| FTSE 100 | 9,894.15 | 24.18 | -0.24% |
| HKSE | 24,699.28 | 316.81 | 1.30% |
| NASDAQ | 21,946.76 | 299.15 | 1.38% |
| Nikkei 225 | 51,910.42 | 394.93 | 0.77% |
| NZX 50 Index | 12,753.24 | 146.48 | -1.14% |
| S&P 500 | 6,581.00 | 74.52 | 1.15% |
| S&P/ASX 200 | 8,393.70 | 110.90 | -1.30% |
| SSE Composite Index | 3,842.09 | 28.81 | 0.76% |